Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Target engagement analysis and link to pharmacodynamic endpoint for a novel class of CNS-penetrant and efficacious p38α MAPK inhibitors.

Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology - 1 Sept 2014

Bachstetter Adam D, Watterson D Martin, Van Eldik Linda J

Abstract excerpt

The protein kinase, p38α MAPK, is a key intracellular transducer of stressor-induced neuroinflammatory responses and, as such, is of high interest as a potential therapeutic target. We recently reported the synthesis and evaluation of first-in-class CNS-penetrant and highly specific p38 MAPK inhibitors that avoid target crossover issues seen in popular small molecule p38 MAPK inhibitors used in hundreds of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytokines
Share to Drug Resistance

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lipopolysaccharides

Share to Neuroglia

Share to Protein Kinase Inhibitors

Share to Pyridazines

Share to Pyridines

Share to Up-Regulation

Source

Open in PubMed Open full text

Identifiers

PMID: 24789302
DOI: 10.1007/s11481-014-9543-3
PMCID: PMC4122817

Genes

CXCL1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Target engagement analysis and link to pharmacodynamic endpoint for a novel class of CNS-penetrant and efficacious p38α MAPK inhibitors.PMID 24789302Read ↗

Selective suppression of the α isoform of p38 MAPK rescues late-stage tau pathologySemantic proximity Read ↗

Targeting MAPAKAP2(MK2) to combat inflammation by avoiding the differential regulation of anti-inflammatory genes by p38 MAPK inhibitorsSemantic proximity Read ↗

An overview of mammalian p38 mitogen-activated protein kinases, central regulators of cell stress and receptor signalingSemantic proximity Read ↗

Perspective on the discovery and scientific impact of p38 MAP kinase.Semantic proximity Read ↗

The p38 MAP kinase pathway as a therapeutic target in inflammatory diseaseSemantic proximity Read ↗

A Special View of What Was Almost Forgotten: p38δ MAPKSemantic proximity Read ↗

The p38alpha mitogen-activated protein kinase limits the CNS proinflammatory cytokine response to systemic lipopolysaccharide, potentially through an IL-10 dependent mechanism.Semantic proximity Read ↗

Plasmalogen-Independent Neuroprotection: Synthetic alkyl ether lipids activate signaling to mitigate neuroinflammation and enhance cognitive functionSemantic proximity Read ↗

Analysis of Mechanistic Pathway Models in Drug Discovery: p38 PathwaySemantic proximity Read ↗

<i>In silico</i> molecular target prediction unveils mebendazole as a potent MAPK14 inhibitorSemantic proximity Read ↗

Masitinib is an oral, brain penetrant inhibitor of microglial and mast cell activity with neuroprotective potential in progressive forms of multiple sclerosisSemantic proximity Read ↗

Control of IL-17 receptor signaling and tissue inflammation by the p38α–MKP-1 signaling axis in a mouse model of multiple sclerosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.